SOFIE Biosciences develops and delivers radiopharmaceuticals and theranostics, operating a PET radiopharmacy and a contract development and manufacturing organization. The company emphasizes molecular diagnostics and therapeutics to improve patient outcomes. It maintains a robust radiopharmaceutical production and distribution network and mature contract manufacturing services. SOFIE also holds high‑value theranostic intellectual property. The company is positioned to scale radiopharmaceutical delivery and commercialize theranostic products, leveraging its existing manufacturing and distribution capabilities. No revenue or user metrics were disclosed in the article. Sofie Biosciences develops diagnostic imaging agents and scanners for Positron Emission Tomography (PET) in vivo molecular imaging. The company aims to increase the adoption and application diversity of PET by enabling quantitative, non-invasive measurement of disease biology. Led by President & CEO Patrick Phelps and COO Philipp Czernin, Sofie focuses on both agents and scanner technologies. It intends to use recent financing to continue development of those diagnostic imaging agents and scanners. Sofie is based in Los Angeles, CA and targets broader clinical and translational PET applications. Sofie Biosciences develops molecular imaging probes and devices to help scientists and physicians investigate the biology of disease. The company focuses on increasing the availability and application base of Positron Emission Tomography (PET) imaging. One notable technology is a self-shielded microfluidic chip-based synthesizer for on-demand PET probe production. Sofie is a spinout of UCLA and Caltech, founded in 2008 and led by President & CEO Patrick Phelps. The company raised $5M in a Series A financing and intends to use the funds to further develop its technologies. Sofie Biosciences develops molecular imaging agents and devices focused on PET imaging to improve diagnosis, treatment selection, and therapeutic monitoring. It holds an exclusive license from the University of California to a family of PET molecular imaging agents called FAC, which have shown promise in preclinical animal research and early patient studies for assessing response to nucleoside prodrugs. The company designs its agents to enable more accurate, whole-body noninvasive determination of therapeutic response. Sofie intends to use recent funding to develop new PET imaging agents and to enhance its PET imaging systems and chemistry units. The company closed an additional $2m from new and existing investors, including the Cycad Group. Sofie is based in Culver City, California, and its founders include Dr. Michael Phelps, Dr. Owen Witte, Dr. Johannes Czernin and Dr. James Heath.

Total raised

$11M

Funding rounds

4

Latest round

Equity

Latest activity

Jun 2016